Related posts

cash, credit and health3 Promising Healthcare Stocks3 Best Cyclical and Value ETFs
Investor Insights

This summary was created by AI, based on 8 opinions in the last 12 months.

Health Care Select Sector SPDR Fund (XLV-N) has received mixed reviews from experts. While some believe that healthcare is a strong and defensive sector with excellent prospects, others are disappointed by its performance and past seasonality. The potential for strong earnings and growth, as well as the expectation of a recession in 2024, are factors to consider. Overall, the outlook for XLV-N is uncertain but could improve in the second half of the year.

Consensus
Mixed
Valuation
Fair Value
BUY

Likes healthcare in general, a larger weight for him. Healthcare has been the leader YTD, only 11 days into the new year. The XLV would make sense for a broad-based, US healthcare strategy. IXJ is the global version of that.

E.T.F.'s
PAST TOP PICK
(A Top Pick May 05/23, Down 7%)

Bought this to be defensive, however, health care wasn't that defensive this year. Now, HC is past seasonality and he doesn't like it.

E.T.F.'s
BUY

The recent inflows into healthcare are based on the new diet drugs like Ozempic. Novo Nordisk and Eli Lilly have benefitted from this trend. These diet drugs are the AI equivalent in healthcare, are blockbusters. 

E.T.F.'s
COMMENT

Parts of healthcare are doing very well: equipment, disposables, more surgical procedures, managed care. Does this translate into stronger earnings and growth even during an economic contraction?

E.T.F.'s
BUY

She picked it to start the year, but it hasn't performed well in the first six months. Healthcare has lagged this year, but when the VIX is this low, you want to hold defence.

E.T.F.'s
BUY

She hopes healthcare picks up in the second half. She feels we're in late cycle where staples and utilities are expensive, but healthcare performs the best among these. HC has underperformed in the first half, but should improve second half or 2024, because XLV holds so many good companies.

E.T.F.'s
BUY

She expects a recession in 2024, and higher unemployment. She sees a lot of opportunity in healthcare.

E.T.F.'s
TOP PICK

Defensive name that provides exposure to health care sector.
Very strong sector as health care demand not going away.
Excellent prospects for healthcare during summer months.

E.T.F.'s
BUY
She's not a fan of ETFs, this single-brushstroke style of investing, but an ETF makes sense in health care, because the companies are very different. Some will excel while others will flame out (considering their drug pipelines).
E.T.F.'s
BUY
As a 5-year hold The valuation is attractive, balance sheet is good and there's non-discretionary demand for the products. Many of the underlying stocks pay a good dividend.
E.T.F.'s
BUY
Is bullish biotech Biotchechs like Insight are up 13%, Moderna 25% and Regeneron 6% so hitting their lows. The whole XLV is up 8.5% off its June 17 low. 91 stocks in the S&P are above their 200-day moving average, and 18 of these are healthcare. This is the best sector to be overweight in.
E.T.F.'s
BUY
Healthcare thrives when economies slow.
E.T.F.'s
BUY
Allan Tong’s Discover Picks XLV ETF’s top holdings are Johnson & Johnson, UnitedHealth Group, Pfizer, Abbott Labs, AbbVie, Thermo Fisher, Merck, Eli Lilly and Danaher. A bullish case can be made for almost all all these names. Another plus: the MER is only 0.1%, though the dividend pays a lowly 1.4%. XLV’s PE is merely 6.62%, volumes average a healthy 14.8 billion a day, and its beta is a very stable 0.73. While you can make better gains holding some of the stocks this ETF holds, XLV is a safe way to play the American healthcare stocks in 2022. Read 3 Promising Healthcare Stocks for our full analysis.
E.T.F.'s
BUY
He likes healthcare, given the return to preventative care and elective surgeries. Also, there's a strong pharma pipeline. Stay long in health.
E.T.F.'s
BUY
Allan Tong’s Discover Picks However, if you want to own several in one place or can’t afford to buy one of these stocks individually, XLV is the place to go. It trades on the Nasdaq. It charges an ultra-low MER of 0.12%, trades at merely 4.18x PE and pays a 1.4% dividend. Also, average volumes are a robust 13.9 million and the Beta is a low 0.71. YTD, XLV has lost 7.55%, but Omicron was the major disruptor and restrictions are quickly lifting now. Essentially, you’re buying this ETF for the future. Read 3 Best Cyclical and Value ETFs for our full analysis.
E.T.F.'s
Showing 1 to 15 of 54 entries

Health Care Select Sector SPDR Fund(XLV-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 6

Stockchase rating for Health Care Select Sector SPDR Fund is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Health Care Select Sector SPDR Fund(XLV-N) Frequently Asked Questions

What is Health Care Select Sector SPDR Fund stock symbol?

Health Care Select Sector SPDR Fund is a American stock, trading under the symbol XLV-N on the NYSE Arca (XLV). It is usually referred to as AMEX:XLV or XLV-N

Is Health Care Select Sector SPDR Fund a buy or a sell?

In the last year, 6 stock analysts published opinions about XLV-N. 6 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Health Care Select Sector SPDR Fund.

Is Health Care Select Sector SPDR Fund a good investment or a top pick?

Health Care Select Sector SPDR Fund was recommended as a Top Pick by on . Read the latest stock experts ratings for Health Care Select Sector SPDR Fund.

Why is Health Care Select Sector SPDR Fund stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Health Care Select Sector SPDR Fund worth watching?

6 stock analysts on Stockchase covered Health Care Select Sector SPDR Fund In the last year. It is a trending stock that is worth watching.

What is Health Care Select Sector SPDR Fund stock price?

On 2024-04-12, Health Care Select Sector SPDR Fund (XLV-N) stock closed at a price of $138.91.